文献速递艾滋病与性传播感染

整合酶抑制剂方案在HIV初治患者中的有效性:欧洲多队列研究

Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

结果显示1年VF和INSTI-DC估计概率分别为5.6%和16.2%,拉替拉韦高于多替拉韦和埃替拉韦;

要点

  • 多替拉韦或埃替拉韦方案在常规实践中显示高有效性。
  • 基线高病毒载量增加病毒学失败风险,高CD4降低风险。
  • 拉替拉韦方案停药风险高于多替拉韦。

核心结论

  • 大型多队列研究表明埃替拉韦或多替拉韦为基础的一线ART在欧洲常规实践中具有高有效性。

主要发现

  • 1年VF和INSTI-DC估计概率分别为5.6%(95%CI 4.5-6.7)和16.2%(95%CI 14.9-17.6),拉替拉韦高于埃替拉韦和多替拉韦。
  • INSTI-DC预测因素包括拉替拉韦vs多替拉韦(aHR 3.03,95%CI 2.34-3.92,P<0.001)、>3种药物vs 3种药物(aHR 2.73,95%CI 1.55-4.79,P<0.001)及多替拉韦可及后启动ART(aHR 0.64,95%CI 0.48-0.83,P=0.001)。
  • 主要INSTI传播耐药突变在2/1114(0.2%)个体中发生。

临床怎么用

  • 优先选择多替拉韦或埃替拉韦为基础的方案。
  • 对基线高病毒载量患者加强病毒学监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: INSTIs have become a pillar of first-line ART. Real-world data are needed to assess their effectiveness in routine care. OBJECTIVES: We analysed ART-naive patients who started INSTI-based regimens in 2012-19 whose data were collected by INTEGRATE, a European collaborative study including seven national cohorts. METHODS: Kaplan-Meier analyses assessed time to virological failure (VF), defined as one viral load (VL) ≥1000 copies/mL, two consecutive VLs ≥50 copies/mL, or one VL ≥50 copies/mL followed by treatment change after ≥24 weeks of follow-up, and time to INSTIs discontinuation (INSTI-DC) for any reason. Factors associated with VF and INSTI-DC were explored by logistic regression analysis. RESULTS: Of 2976 regimens started, 1901 (63.9%) contained dolutegravir, 631 (21.2%) elvitegravir and 444 (14.9%) raltegravir. The 1 year estimated probabilities of VF and INSTI-DC were 5.6% (95% CI 4.5-6.7) and 16.2% (95% CI 14.9-17.6), respectively, and were higher for raltegravir versus both elvitegravir and dolutegravir. A baseline VL ≥100 000 copies/mL [adjusted HR (aHR) 2.17, 95% CI 1.55-3.04, P < 0.001] increased the risk of VF, while a pre-treatment CD4 count ≥200 cells/mm3 reduced the risk (aHR 0.52, 95% CI 0.37-0.74, P < 0.001). Predictors of INSTI-DC included use of raltegravir versus dolutegravir (aHR 3.03, 95% CI 2.34-3.92, P < 0.001), use of >3 drugs versus 3 drugs (aHR 2.73, 95% CI 1.55-4.79, P < 0.001) and starting ART following availability of dolutegravir (aHR 0.64, 95% CI 0.48-0.83, P = 0.001). Major INSTI mutations indicative of transmitted drug resistance occurred in 2/1114 (0.2%) individuals. CONCLUSIONS: This large multi-cohort study indicates high effectiveness of elvitegravir- or dolutegravir-based first-line ART in routine practice across Europe.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Rossetti B, Fabbiani M, Di Carlo D, et al. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study. J Antimicrob Chemother. 2021. PMID: 34212176. doi:10.1093/jac/dkab200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。